Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: a case report

BACKGROUND: Mepolizumab (MEP) is the first anti Interleukin (IL)-5 add-on therapy approved for the treatment of severe refractory eosinophilic asthma. CASE PRESENTATION: We describe here the case of a 49 years-old woman with Aspirin-exacerbated respiratory disease (AERD), chronic rhinosinusitis, nas...

Descripción completa

Detalles Bibliográficos
Autores principales: Caruso, C., Colantuono, S., Pugliese, D., Di Mario, C., Tolusso, B., Gremese, E., Papparella, G., Castrì, F., Gasbarrini, A., Romano, A., Armuzzi, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178951/
https://www.ncbi.nlm.nih.gov/pubmed/32336975
http://dx.doi.org/10.1186/s13223-020-00423-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178951/
https://www.ncbi.nlm.nih.gov/pubmed/32336975
http://dx.doi.org/10.1186/s13223-020-00423-3

Ejemplares similares